NASDAQ:DBVT

Dbv Technologies S.a Stock News

etoro logo Buy DBVT
*Your capital is at risk
$15.82
+0.0900 (+0.572%)
At Close: Jul 02, 2026
A risk management process slowed the launch of Aimmune’s first product.
Montrouge, France, March 4, 2020 DBV Technologies Reports Full-Year 2019 Financial Results and Provides Business Update Advisory Committee meeting to be held on May.
DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the settlement and delivery of an

DBV Technologies FY19 EPS €(4.15)

12:00am, Wednesday, 04'th Mar 2020
DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the underwriters for its pre
The president’s State of the Union address was wide-ranging, as they tend to be, but those who tuned in heard mention of two hot health policy topics:
Shares of biopharma Aimmune Therapeutics Inc (NASDAQ: AIMT ) advanced strongly in after-hours trading Friday following a positive FDA verdict for Aimunne's peanut allergy drug. 9-Year Wait Ends The FD

70 Biggest Movers From Yesterday

12:00am, Friday, 31'st Jan 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 29) 10X Genomics Inc (NASDAQ: TXG ) Agile Therapeutics
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE